Elite Health Systems Burns Cash, Secures Key Medicare Advantage Approvals

TL;DR

**EHSI is a speculative bet on future Medicare Advantage revenue, currently burning cash with no sales, so proceed with extreme caution.**

AI Summary

Elite Health Systems Inc. (EHSI) reported no revenue for the three and six months ended June 30, 2025, and 2024, as it is in the development stage of establishing Medicare Advantage plans. The company incurred a net loss of $441,000 for the three months ended June 30, 2025, compared to a net loss of $435,000 for the same period in 2024. For the six months ended June 30, 2025, the net loss was $865,000, an increase from $747,000 in the prior year period. Selling, general, and administrative expenses were $445,000 for the three months ended June 30, 2025, and $872,000 for the six months ended June 30, 2025. Cash and cash equivalents decreased from $4,034,000 at December 31, 2024, to $3,121,000 at June 30, 2025. The company successfully raised $5,825,000 through the private sale of 11,650,000 shares of common stock and issued 475,000 shares as compensation, bringing total outstanding shares to 21,409,924 as of June 30, 2025. EHSI received conditional approval for a Knox-Keene license in California in May 2025 and conditional CMS approval for its CY 2026 Medicare Advantage application in June 2025, marking a strategic shift from its former radiation treatment center business.

Why It Matters

For investors, EHSI's continued lack of revenue and increasing net losses, alongside a significant accumulated deficit of $5,310,000, signal high risk. The conditional CMS approval for its Medicare Advantage plan in California is a critical milestone, but the company's ability to secure final approval, build a provider network, and enroll subscribers will dictate its future. Employees and customers are directly impacted by the success of this pivot to managed care, as the company's viability hinges on its ability to generate revenue from these new plans. In the competitive healthcare market, EHSI faces an uphill battle against established Medicare Advantage providers, making its capital-raising efforts and operational execution paramount.

Risk Assessment

Risk Level: high — The company reported no revenue for the three and six months ended June 30, 2025, and incurred net losses of $441,000 and $865,000, respectively, for these periods. Its accumulated deficit reached $5,310,000 at June 30, 2025, and cash and cash equivalents declined by $913,000 in the first six months of 2025, raising substantial doubt about its ability to continue as a going concern.

Analyst Insight

Investors should monitor EHSI closely for updates on final CMS approval and subscriber enrollment, as these are critical for revenue generation. Given the high risk and current lack of revenue, a 'wait and see' approach is advisable, or consider a small, highly speculative position only if comfortable with potential total loss.

Financial Highlights

debt To Equity

0.05

revenue

$0

operating Margin

N/A

total Assets

$3,984,000

total Debt

$197,000

net Income

-$441,000

eps

-$0.02

gross Margin

N/A

cash Position

$3,121,000

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for Q2 2025 or H1 2025, indicating development stage.)
• -$441,000 — Net Loss (Q2 2025) (Increased from -$435,000 in Q2 2024, reflecting ongoing operational costs without revenue.)
• -$865,000 — Net Loss (H1 2025) (Increased from -$747,000 in H1 2024, showing growing losses as the company develops.)
• $5,310,000 — Accumulated Deficit (Increased from $4,445,000 at Dec 31, 2024, highlighting significant historical losses.)
• $3,121,000 — Cash and Cash Equivalents (Decreased from $4,034,000 at Dec 31, 2024, indicating cash burn for operations.)
• $5,825,000 — Capital Raised (Through private sale of 11,650,000 common shares, crucial for funding operations.)
• 21,409,924 — Common Shares Outstanding (As of June 30, 2025, reflecting significant share issuance for capital.)
• May 2025 — Knox-Keene License Awarded (Key regulatory approval for operating managed health care plans in California.)
• June 2025 — CMS Conditional Approval (Critical step towards operating a Medicare Advantage plan for CY 2026.)
• $2,000,000 - $5,000,000 — Planned Private Placement (Expected proceeds from a July 2025 offering, vital for continued funding.)

Key Players & Entities

• Elite Health Systems Inc. (company) — Registrant and parent company
• U.S. NeuroSurgical Holdings, Inc. (company) — Former name of Elite Health Systems Inc.
• Elite Health Plan, Inc. (company) — Wholly-owned subsidiary awarded Knox-Keene license
• Centers for Medicare and Medicaid Services (regulator) — Granted conditional approval for Medicare Advantage application
• $441,000 (dollar_amount) — Net loss for the three months ended June 30, 2025
• $865,000 (dollar_amount) — Net loss for the six months ended June 30, 2025
• $5,310,000 (dollar_amount) — Accumulated deficit at June 30, 2025
• $3,121,000 (dollar_amount) — Cash and cash equivalents at June 30, 2025
• $5,825,000 (dollar_amount) — Proceeds from private sale of common stock
• 21,409,924 (dollar_amount) — Shares of common stock outstanding as of June 30, 2025

FAQ

Risk Factors

• Regulatory Approval Delays [high — regulatory]: EHSI received conditional approval for its Knox-Keene license in May 2025 and conditional CMS approval for its CY 2026 Medicare Advantage application in June 2025. Any further delays or failure to obtain final approvals could significantly impede the company's ability to launch its core business and generate revenue.
• Cash Burn and Funding Needs [high — financial]: The company has a net loss of $441,000 for Q2 2025 and $865,000 for H1 2025. Cash and cash equivalents decreased from $4,034,000 to $3,121,000. While $5,825,000 was raised in a private placement, the planned $2M-$5M private placement in July 2025 indicates ongoing substantial funding requirements to cover operational expenses until revenue generation.
• Transition from Former Business [medium — operational]: EHSI is transitioning from its former radiation treatment center business to establishing Medicare Advantage plans. This strategic shift involves significant operational changes, new regulatory compliance, and market entry challenges that could impact execution.
• Competition in Medicare Advantage Market [medium — market]: The Medicare Advantage market is highly competitive, with established players and evolving regulations. EHSI will face challenges in acquiring members and competing on price, benefits, and network quality against larger, more experienced insurers.
• Accumulated Deficit [medium — financial]: The accumulated deficit increased to $5,310,000 as of June 30, 2025, from $4,445,000 at December 31, 2024. This substantial historical loss highlights the company's long path to profitability and reliance on external funding.

Industry Context

The Medicare Advantage market is a rapidly growing segment of the US healthcare industry, driven by an aging population and government incentives. However, it is also highly competitive, with established national insurers and regional players vying for market share. Regulatory changes from CMS significantly impact plan offerings, reimbursement rates, and operational requirements, demanding constant adaptation from participating entities.

Regulatory Implications

EHSI's success is heavily contingent on navigating complex regulatory landscapes. Obtaining and maintaining licenses like the Knox-Keene in California and securing ongoing CMS approval for Medicare Advantage plans are critical. Any shifts in government policy, reimbursement structures, or compliance requirements could materially affect EHSI's business model and financial viability.

What Investors Should Do

1. Monitor regulatory approval progress closely.
2. Evaluate cash burn rate and future funding needs.
3. Assess competitive positioning and member acquisition strategy.

Key Dates

• 2025-05-01: Conditional Knox-Keene License Approval — This is a critical step for EHSI to operate managed health care plans in California, a key market for its Medicare Advantage strategy.
• 2025-06-01: Conditional CMS Approval for CY 2026 Medicare Advantage — This approval is essential for EHSI to offer Medicare Advantage plans in the upcoming enrollment cycle, validating its strategic direction.
• 2025-06-30: End of Q2 2025 — Reported $0 revenue, a net loss of $441,000, and cash reserves of $3,121,000, highlighting ongoing development costs and cash burn.
• 2025-07-01: Planned Private Placement — An expected $2,000,000 - $5,000,000 in proceeds will be crucial for funding operations and continued development efforts.
• 2024-12-31: End of Fiscal Year 2024 — Company had $4,034,000 in cash and cash equivalents and an accumulated deficit of $4,445,000, providing a baseline for current period changes.

Glossary

Knox-Keene License

A license required by the California Department of Managed Health Care (DMHC) for entities to operate as health care service plans in California. (Essential for EHSI to legally offer its Medicare Advantage plans within California.)

CMS

Centers for Medicare & Medicaid Services, a federal agency that administers Medicare and Medicaid. (CMS approval is mandatory for EHSI to participate in and offer Medicare Advantage plans.)

Medicare Advantage

A type of Medicare health plan offered by private companies approved by Medicare. These plans cover Medicare benefits and may offer extra benefits. (This is the core business EHSI is developing and aims to operate.)

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. It represents a deficit in the company's equity. (Indicates the company's historical unprofitability and reliance on funding to cover losses.)

Stock Subscriptions Receivable

Amounts owed to the company by individuals or entities who have agreed to purchase stock but have not yet paid in full. (A reduction in this line item from $175,000 to $0 suggests that prior stock purchase commitments have been settled or are no longer expected.)

Year-Over-Year Comparison

Compared to the prior year period, EHSI continues to report no revenue, indicating its development stage persists. The net loss for the three months ended June 30, 2025, increased slightly to $441,000 from $435,000 in 2024, while the six-month loss widened from $747,000 to $865,000, reflecting increased operational expenses. Cash reserves have decreased by approximately $913,000, necessitating significant capital raises to sustain operations. New risks related to the transition from its former business and the critical need for regulatory approvals have emerged as key focus areas.

Key Financial Figures

• $0.01 — hares of the registrant's common stock, $0.01 par value, outstanding as of August 13,

Filing Documents

• usnu20250630_10q.htm (10-Q) — 568KB
• ex_850009.htm (EX-31.1) — 12KB
• ex_850010.htm (EX-31.2) — 13KB
• ex_850011.htm (EX-32.1) — 5KB
• 0001437749-25-026553.txt ( ) — 3253KB
• ehsi-20250630.xsd (EX-101.SCH) — 30KB
• ehsi-20250630_def.xml (EX-101.DEF) — 235KB
• ehsi-20250630_lab.xml (EX-101.LAB) — 169KB
• ehsi-20250630_pre.xml (EX-101.PRE) — 247KB
• ehsi-20250630_cal.xml (EX-101.CAL) — 27KB
• usnu20250630_10q_htm.xml (XML) — 346KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3 Item 1.

Financial Statements

Financial Statements 3 Item 2. Management Discussion and Analysis of Financial Condition and Results of Operations. 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 21 Item 4.

Controls and Procedures

Controls and Procedures 21

– OTHER INFORMATION

PART II – OTHER INFORMATION 23 Item 1.

Legal Proceedings

Legal Proceedings 23 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 24 Item 4. Submission of Matters to a Vote of Security Holders 24 Item 5. Other Information 24 Item 6. Exhibits 24

SIGNATURES

SIGNATURES 25 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 (Unaudited) (Audited) ASSETS Current assets: Cash and cash equivalents $ 3,121,000 $ 4,034,000 Other current assets 40,000 28,000 Due from related parties 1,000 12,000 Stock subscriptions receivable - 175,000 Total current assets 3,162,000 4,249,000 Property and equipment: Capitalized software under development 767,000 - Operating lease right-of-use asset 55,000 72,000 Total property and equipment 822,000 72,000 TOTAL ASSETS $ 3,984,000 $ 4,321,000 LIABILITIES Current liabilities: Operating lease right-of-use liability - current portion $ 36,000 $ 34,000 Accounts payable and accrued expenses 131,000 60,000 Total current liabilities 167,000 94,000 Operating lease right-of-use liability - net of current portion 19,000 38,000 Guarantee liability 11,000 11,000 Total liabilities 197,000 143,000 EQUITY Common stock - par value $ .01 ; 25,000,000 shares authorized; 21,409,924 and 19,984,924 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. 214,000 200,000 Stock to be issued - 238,000 Additional paid-in capital 8,883,000 8,185,000 Accumulated deficit ( 5,310,000 ) ( 4,445,000 ) Total stockholders' equity 3,787,000 4,178,000 TOTAL LIABILITIES AND EQUITY $ 3,984,000 $ 4,321,000 See accompanying notes to the consolidated financial statements 3 Table of Contents ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended June 30, 2025 2024 Revenue $ - $ - Costs and expenses: Selling, general and administrative 445,000 437,000 Total expense 445,000 437,000 Operating Income ( loss) ( 445,000 ) ( 437,000 ) Total other income (expense) Interest income (expense) 4,000 -

View Full Filing

View this 10-Q filing on SEC EDGAR